非那雄胺间歇给药维持良性前列腺增生疗效的临床研究  

A clinical study on intermittent finasteride therapy for benign prostatic hyperplasia

作　　者：杜跃军[1] 娄艳[2] 谭万龙[1] 郑少斌[1] 

机构地区：[1]南方医科大学南方医院泌尿外科,广东广州510515 [2]南方医科大学南方医院药材科,广东广州510515

出　　处：《现代泌尿外科杂志》2011年第4期319-321,共3页Journal of Modern Urology

摘　　要：目的验证非那雄胺间歇给药维持良性前列腺增生（BPH）疗效的可行性并观察间歇给药是否能够减少勃起功能障碍、性欲减退等性功能相关不良反应的发生率。方珐收集泌尿外科门诊符合入组条件的60例患者，将受试者均分为3组，分别予非那雄胺（保列治）5mg1次／d、1次／2d及1次／3d口服，进行为其6个月的随访。以国际前列腺症状评分（IPSS）、生活质量评分（QOL）、前列腺特异性抗原（PSA）、最大尿流率（Qmax）及超声测量作为治疗有效性参数，以勃起功能障碍国际问卷5（IIEF-5）作为治疗前后性功能评价参数。结果1次／3d给药组多数患者于试验开始后2～3周出现明显症状加重，提前终止该组实验。随访1次／d及1次／2d给药组6个月，1次／2d给药组勃起功能障碍发生率略低于1次／d给药组。结论非那雄胺隔日间歇给药可能能够达到维持BPH疗效、减少药物副反应的目的，但这一推断尚需通过更大规模的随机、双盲多中心试验进行证实。Objective To evaluate the outcome of intermittent finasteride for the treatment of benign prostatic hyperplasia （BPH）. Methods 60 patients with BPH were equally divided into 3 groups at random, including l/d, 1/2ds and 1/3ds finasteride intaking groups. All the patients were followed up for 6 months. IPSS score, QOL score, serum level of PSA, Qmax, date from ultrasound examination and evaluation of IIEF-5 were observed. Results The study on 1/3ds finasteride intaking group was cancelled ahead of schedule for high incidence of exacerbation. No significant difference was found between the 1/d and 1/2ds groups. ConclusiONS 1/2ds intermittent finasteride intake may be as effective as daily administration for the treatment of BPH.

关 键 词：前列腺增生 非那雄胺 治疗 

分 类 号：R691.2[医药卫生—泌尿科学]